David Emerson Jorden

Insider · CEO/CFO · AURX

David Emerson Jorden files insider transactions with the SEC as a ceo/cfo of Nuo Therapeutics (AURX). We hold 2 disclosed purchases and sales filed since 21 August 2008, 2 of them in the last 90 days.

Files forAURX
Disclosed buys and sells2 in all, 2 in the last 90 days
Last disclosure31 August 2026

Positions held

11 posts we hold — a term names its own dates; a run of filings only says when they filed

Filed 10 August 2017 — 28 August 2026CEO/CFO · Nuo Therapeutics (AURX)49 Form 4 lines · source: SEC Form 4
Filed 19 April 2017 — 14 June 2017Acting Chief Financial Officer · PLx Pharma (PLXP)4 Form 4 lines · source: SEC Form 4
Filed 5 May 2016 — 9 January 2017CEO, CFO · Nuo Therapeutics (NONE)6 Form 4 lines · source: SEC Form 4
Filed 9 July 2015 — 9 July 2015Acting CFO · Nuo Therapeutics (NUOT)1 Form 4 line · source: SEC Form 4
Filed 14 May 2009 — 24 September 2013Acting Chief Financial Officer · Opexa Therapeutics (OPXA)28 Form 4 lines · source: SEC Form 4
Filed 18 January 2011 — 21 May 2013Director · Cytomedix (CMXI)57 Form 4 lines · source: SEC Form 4
Filed 15 April 2011 — 1 December 2011Director and 10% owner · Cytomedix (CMXI.OB)2 Form 4 lines · source: SEC Form 4
Filed 8 December 2008 — 25 January 2011Director and 10% owner · Cytomedix (GTF)82 Form 4 lines · source: SEC Form 4
Filed 30 September 2008 — 8 June 2010Director · Cytomedix (CTF)2 Form 4 lines · source: SEC Form 4
Filed 19 August 2008 — 16 November 2009Director · Opexa Therapeutics (opxa)14 Form 4 lines · source: SEC Form 4
Filed 30 January 2009 — 26 May 2009Director · Cytomedix (GFT)4 Form 4 lines · source: SEC Form 4

Everything they disclosed

120 entries, newest first — one per disclosure report, one per Form 4 line

▲ bought on the open market 789 shares of Nuo TherapeuticsSEC Form 431 August 2026Common Stock · traded 27 August 2026 · filed 31 August 2026
▲ bought on the open market 7,984 shares of Nuo TherapeuticsSEC Form 431 August 2026Common Stock · traded 28 August 2026 · filed 31 August 2026
was granted 789 shares of Nuo TherapeuticsSEC Form 428 August 2026Common Stock · traded 27 August 2026 · filed 28 August 2026
was granted 7,984 shares of Nuo TherapeuticsSEC Form 428 August 2026Common Stock · traded 28 August 2026 · filed 28 August 2026
exercised options over 162,500 shares of Nuo TherapeuticsSEC Form 42 July 2026Common Stock · traded 30 June 2026 · filed 2 July 2026
had shares withheld for tax on 160,892 shares of Nuo TherapeuticsSEC Form 42 July 2026Common Stock · traded 30 June 2026 · filed 2 July 2026
exercised options over 162,500 shares of Nuo Therapeutics (a derivative holding)SEC Form 42 July 2026Option to purchase common stock · traded 30 June 2026 · filed 2 July 2026
was granted 125,000 shares of Nuo Therapeutics (a derivative holding)SEC Form 42 July 2026Option to purchase common stock · traded 29 June 2026 · filed 2 July 2026
was granted 13,245 shares of Nuo TherapeuticsSEC Form 45 June 2026Common Stock · traded 5 June 2026 · filed 5 June 2026
exercised options over 125,000 shares of Nuo TherapeuticsSEC Form 45 January 2026Common Stock · traded 1 January 2026 · filed 5 January 2026
had shares withheld for tax on 25,381 shares of Nuo TherapeuticsSEC Form 45 January 2026Common Stock · traded 1 January 2026 · filed 5 January 2026
exercised options over 125,000 shares of Nuo Therapeutics (a derivative holding)SEC Form 45 January 2026Option to purchase common stock · traded 31 December 2018 · filed 5 January 2026
exercised options over 125,000 shares of Nuo Therapeutics (a derivative holding)SEC Form 45 January 2026Option to purchase common stock · traded 31 December 2018 · filed 5 January 2026
exercised options over 125,000 shares of Nuo TherapeuticsSEC Form 45 January 2026Common Stock · traded 1 January 2026 · filed 5 January 2026
had shares withheld for tax on 25,381 shares of Nuo TherapeuticsSEC Form 45 January 2026Common Stock · traded 1 January 2026 · filed 5 January 2026
▼ sold on the open market 200,000 shares of Nuo TherapeuticsSEC Form 43 December 2025Common Stock · traded 28 November 2025 · filed 3 December 2025
exercised options over 192,710 shares of Nuo Therapeutics (a derivative holding)SEC Form 44 August 2025Option to purchase common stock · traded 9 August 2018 · filed 4 August 2025
exercised options over 100,000 shares of Nuo TherapeuticsSEC Form 44 August 2025Common Stock · traded 1 August 2025 · filed 4 August 2025
exercised options over 92,710 shares of Nuo TherapeuticsSEC Form 44 August 2025Common Stock · traded 1 August 2025 · filed 4 August 2025
had shares withheld for tax on 21,313 shares of Nuo TherapeuticsSEC Form 44 August 2025Common Stock · traded 1 August 2025 · filed 4 August 2025
▼ sold on the open market 30,000 shares of Nuo TherapeuticsSEC Form 414 November 2022Common Stock · traded 9 November 2022 · filed 14 November 2022
▼ sold on the open market 30,000 shares of Nuo TherapeuticsSEC Form 414 November 2022Common Stock · traded 9 November 2022 · filed 14 November 2022
▼ sold on the open market 27,000 shares of Nuo TherapeuticsSEC Form 414 November 2022Common Stock · traded 9 November 2022 · filed 14 November 2022
▼ sold on the open market 20,000 shares of Nuo TherapeuticsSEC Form 414 November 2022Common Stock · traded 9 November 2022 · filed 14 November 2022
▼ sold on the open market 20,000 shares of Nuo TherapeuticsSEC Form 414 November 2022Common Stock · traded 9 November 2022 · filed 14 November 2022
▼ sold on the open market 13,500 shares of Nuo TherapeuticsSEC Form 414 November 2022Common Stock · traded 9 November 2022 · filed 14 November 2022
▼ sold on the open market 10,000 shares of Nuo TherapeuticsSEC Form 414 November 2022Common Stock · traded 9 November 2022 · filed 14 November 2022
▼ sold on the open market 7,000 shares of Nuo TherapeuticsSEC Form 414 November 2022Common Stock · traded 9 November 2022 · filed 14 November 2022
▼ sold on the open market 5,000 shares of Nuo TherapeuticsSEC Form 414 November 2022Common Stock · traded 9 November 2022 · filed 14 November 2022
was granted 10,532 shares of Nuo TherapeuticsSEC Form 42 May 2022Common Stock · traded 29 April 2022 · filed 2 May 2022
was granted 15,000 shares of Nuo Therapeutics (a derivative holding)SEC Form 426 April 2022Warrants to purchase Common Stock · traded 15 November 2019 · filed 26 April 2022
was granted 30,000 shares of Nuo Therapeutics (a derivative holding)SEC Form 426 April 2022Warrants to purchase Common Stock · traded 6 December 2019 · filed 26 April 2022
was granted 397,635 shares of Nuo Therapeutics (a derivative holding)SEC Form 426 April 2022Warrants to purchase Common Stock · traded 5 October 2020 · filed 26 April 2022
returned to the issuer 45,000 shares of Nuo Therapeutics (a derivative holding)SEC Form 426 April 2022Warrants to purchase Common Stock · traded 5 October 2020 · filed 26 April 2022
was granted 900,000 shares of Nuo Therapeutics (a derivative holding)SEC Form 426 April 2022Warrants to purchase Common Stock · traded 5 October 2020 · filed 26 April 2022
was granted 300,000 shares of Nuo TherapeuticsSEC Form 426 April 2022Common Stock · traded 5 October 2020 · filed 26 April 2022
was granted 82,545 shares of Nuo TherapeuticsSEC Form 426 April 2022Common Stock · traded 5 October 2020 · filed 26 April 2022
was granted 50,000 shares of Nuo TherapeuticsSEC Form 426 April 2022Common Stock · traded 5 October 2020 · filed 26 April 2022
was granted 1,297,635 shares of Nuo Therapeutics (a derivative holding)SEC Form 426 April 2022Warrants to purchase Common Stock · traded 1 December 2021 · filed 26 April 2022
returned to the issuer 900,000 shares of Nuo Therapeutics (a derivative holding)SEC Form 426 April 2022Warrants to purchase Common Stock · traded 1 December 2021 · filed 26 April 2022
returned to the issuer 397,635 shares of Nuo Therapeutics (a derivative holding)SEC Form 426 April 2022Warrants to purchase Common Stock · traded 1 December 2021 · filed 26 April 2022
acquired or disposed of, other 160,000 shares of Nuo Therapeutics (a derivative holding)SEC Form 426 April 2022Warrants to purchase Common Stock · traded 6 December 2021 · filed 26 April 2022
exercised options over 1,137,635 shares of Nuo Therapeutics (a derivative holding)SEC Form 426 April 2022Warrants to purchase Common Stock · traded 30 December 2021 · filed 26 April 2022
exercised options over 1,137,635 shares of Nuo TherapeuticsSEC Form 426 April 2022Common Stock · traded 30 December 2021 · filed 26 April 2022
was granted 66,672 shares of Nuo Therapeutics (a derivative holding)SEC Form 426 April 2022Option to Purchase Common Stock · traded 4 March 2022 · filed 26 April 2022
was granted 125,000 shares of Nuo Therapeutics (a derivative holding)SEC Form 426 April 2022Option to Purchase Common Stock · traded 4 March 2022 · filed 26 April 2022
was granted 125,000 shares of Nuo Therapeutics (a derivative holding)SEC Form 43 January 2019Option to Purchase Common Stock · traded 1 January 2019 · filed 3 January 2019
was granted 192,710 shares of Nuo Therapeutics (a derivative holding)SEC Form 413 August 2018Option to Purchase Common Stock · traded 9 August 2018 · filed 13 August 2018
▲ bought on the open market 247,500 shares of Nuo TherapeuticsSEC Form 414 August 2017COMMON STOCK · traded 10 August 2017 · filed 14 August 2017
▲ bought on the open market 32,727 shares of PLx PharmaSEC Form 416 June 2017Common Stock · traded 14 June 2017 · filed 16 June 2017
▲ bought on the open market 32,727 shares of PLx Pharma (a derivative holding)SEC Form 416 June 2017Warrant · traded 14 June 2017 · filed 16 June 2017
was granted 119,186 shares of PLx PharmaSEC Form 420 April 2017Common Stock · traded 19 April 2017 · filed 20 April 2017
was granted 33,753 shares of PLx Pharma (a derivative holding)SEC Form 420 April 2017Options · traded 19 April 2017 · filed 20 April 2017
was granted 162,500 shares of Nuo Therapeutics (a derivative holding)SEC Form 411 January 2017Option to purchase Common Stock · traded 9 January 2017 · filed 11 January 2017
▲ bought on the open market 137,500 shares of Nuo TherapeuticsSEC Form 429 July 2016Common Stock, par value $0.0001 per share · traded 5 May 2016 · filed 29 July 2016
acquired or disposed of, other 54,049 shares of Nuo TherapeuticsSEC Form 429 July 2016Common Stock, par value $0.0001 per share · traded 5 May 2016 · filed 29 July 2016
acquired or disposed of, other 62,182 shares of Nuo TherapeuticsSEC Form 429 July 2016Common Stock, par value $0.0001 per share · traded 5 May 2016 · filed 29 July 2016
acquired or disposed of, other 55,915 shares of Nuo TherapeuticsSEC Form 429 July 2016Common Stock, par value $0.0001 per share · traded 5 May 2016 · filed 29 July 2016
acquired or disposed of, other 167 shares of Nuo TherapeuticsSEC Form 429 July 2016Common Stock, par value $0.0001 per share · traded 5 May 2016 · filed 29 July 2016
was granted 250,000 shares of Nuo Therapeutics (a derivative holding)SEC Form 415 July 2015Employee Stock Option (right to buy) · traded 9 July 2015 · filed 15 July 2015
converted an unstated number of shares of Opexa Therapeutics (a derivative holding)SEC Form 426 September 2013Convertible Promissory Note · traded 24 September 2013 · filed 26 September 2013
converted 61,912 shares of Opexa TherapeuticsSEC Form 426 September 2013Common Stock · traded 24 September 2013 · filed 26 September 2013
was granted 4,450 shares of Opexa TherapeuticsSEC Form 42 July 2013Common Stock · traded 30 June 2013 · filed 2 July 2013
▲ bought on the open market 25,000 shares of CytomedixSEC Form 421 May 2013COMMON STOCK · traded 17 May 2013 · filed 21 May 2013
▲ bought on the open market 55,000 shares of CytomedixSEC Form 421 May 2013COMMON STOCK · traded 21 May 2013 · filed 21 May 2013
was granted 5,000 shares of Opexa Therapeutics (a derivative holding)SEC Form 41 May 2013Stock Option (Right to Buy) · traded 29 April 2013 · filed 1 May 2013
was granted 17,143 shares of Opexa Therapeutics (a derivative holding)SEC Form 41 May 2013Stock Option (Right to Buy) · traded 29 April 2013 · filed 1 May 2013
▲ bought on the open market 15,000 shares of CytomedixSEC Form 419 April 2013Common Stock · traded 17 April 2013 · filed 19 April 2013
▲ bought on the open market 20,000 shares of CytomedixSEC Form 419 April 2013Common Stock · traded 18 April 2013 · filed 19 April 2013
▲ bought on the open market 15,000 shares of CytomedixSEC Form 419 April 2013Common Stock · traded 19 April 2013 · filed 19 April 2013
▲ bought on the open market 43,485 shares of CytomedixSEC Form 49 April 2013COMMON STOCK · traded 8 April 2013 · filed 9 April 2013
▲ bought on the open market 31,515 shares of CytomedixSEC Form 49 April 2013COMMON STOCK · traded 9 April 2013 · filed 9 April 2013
returned to the issuer an unstated number of shares of Opexa Therapeutics (a derivative holding)SEC Form 427 February 2013Convertible Promissory Note · traded 26 February 2013 · filed 27 February 2013
▲ bought on the open market 20,600 shares of CytomedixSEC Form 427 February 2013COMMON STOCK · traded 26 February 2013 · filed 27 February 2013
▲ bought on the open market 4,400 shares of CytomedixSEC Form 427 February 2013COMMON STOCK · traded 27 February 2013 · filed 27 February 2013
▲ bought on the open market 30,000 shares of CytomedixSEC Form 422 February 2013Common Stock · traded 21 February 2013 · filed 22 February 2013
▲ bought on the open market 20,000 shares of CytomedixSEC Form 422 February 2013Common Stock · traded 22 February 2013 · filed 22 February 2013
▲ bought on the open market 114,286 shares of Cytomedix (a derivative holding)SEC Form 421 February 2013COMMON STOCK WARRANT · traded 19 February 2013 · filed 21 February 2013
was granted 5,278 shares of Opexa Therapeutics (a derivative holding)SEC Form 431 January 2013Common Stock Warrant (Right to Buy) · traded 29 January 2013 · filed 31 January 2013
was granted 4,595 shares of Opexa TherapeuticsSEC Form 424 January 2013Common Stock · traded 31 December 2012 · filed 24 January 2013
was granted 37,500 shares of Opexa Therapeutics (a derivative holding)SEC Form 424 January 2013Convertible Promissory Note · traded 23 January 2013 · filed 24 January 2013
was granted an unstated number of shares of Opexa Therapeutics (a derivative holding)SEC Form 424 January 2013Common Stock Warrant (Right to Buy) · traded 23 January 2013 · filed 24 January 2013
▲ bought on the open market 25,000 shares of CytomedixSEC Form 414 September 2012Common Stock · traded 14 September 2012 · filed 14 September 2012
▲ bought on the open market 8,333 shares of CytomedixSEC Form 412 September 2012Common Stock · traded 11 September 2012 · filed 12 September 2012
exercised in-the-money options over 16,667 shares of Cytomedix (a derivative holding)SEC Form 431 August 2012Warrant · traded 29 August 2012 · filed 31 August 2012
exercised in-the-money options over 16,667 shares of CytomedixSEC Form 431 August 2012Common Stock · traded 29 August 2012 · filed 31 August 2012
was granted 75,000 shares of Opexa Therapeutics (a derivative holding)SEC Form 416 August 2012Stock Option (Right to Buy) · traded 15 August 2012 · filed 16 August 2012
was granted 107,813 shares of Opexa Therapeutics (a derivative holding)SEC Form 427 July 2012Convertible Promissory Note · traded 25 July 2012 · filed 27 July 2012
was granted an unstated number of shares of Opexa Therapeutics (a derivative holding)SEC Form 427 July 2012Common Stock Warrant (Right to Buy) · traded 25 July 2012 · filed 27 July 2012
was granted 10,000 shares of Opexa Therapeutics (a derivative holding)SEC Form 45 March 2012Stock Option (Right to Buy) · traded 1 March 2012 · filed 5 March 2012
was granted 20,600 shares of Opexa Therapeutics (a derivative holding)SEC Form 45 March 2012Stock Option (Right to Buy) · traded 1 March 2012 · filed 5 March 2012
exercised in-the-money options over 200,000 shares of Cytomedix (a derivative holding)SEC Form 415 February 2012Warrant · traded 15 February 2012 · filed 15 February 2012
exercised in-the-money options over 178,571 shares of Cytomedix (a derivative holding)SEC Form 415 February 2012Warrant · traded 15 February 2012 · filed 15 February 2012
▼ sold on the open market 39,775 shares of CytomedixSEC Form 415 February 2012Common Stock · traded 13 February 2012 · filed 15 February 2012
▼ sold on the open market 27,000 shares of CytomedixSEC Form 415 February 2012Common Stock · traded 14 February 2012 · filed 15 February 2012
▼ sold on the open market 76,313 shares of CytomedixSEC Form 415 February 2012Common Stock · traded 15 February 2012 · filed 15 February 2012
exercised in-the-money options over 200,000 shares of CytomedixSEC Form 415 February 2012Common Stock · traded 15 February 2012 · filed 15 February 2012
exercised in-the-money options over 178,571 shares of CytomedixSEC Form 415 February 2012Common Stock · traded 15 February 2012 · filed 15 February 2012
converted 143,370 shares of CytomedixSEC Form 410 February 2012Common Stock · traded 8 February 2012 · filed 10 February 2012
acquired or disposed of, other 8,000 shares of CytomedixSEC Form 410 February 2012Common Stock · traded 8 February 2012 · filed 10 February 2012
acquired or disposed of, other 1,854 shares of CytomedixSEC Form 430 January 2012Common Stock · traded 17 January 2012 · filed 30 January 2012
was granted 50,000 shares of Cytomedix (a derivative holding)SEC Form 46 December 2011Options to Purchase Shares of Common Stock · traded 1 December 2011 · filed 6 December 2011
acquired or disposed of, other 3,793 shares of CytomedixSEC Form 417 October 2011Common Stock · traded 17 October 2011 · filed 17 October 2011
acquired or disposed of, other 5,000 shares of CytomedixSEC Form 418 July 2011Common Stock · traded 15 July 2011 · filed 18 July 2011
▲ bought on the open market 22,500 shares of CytomedixSEC Form 47 June 2011Common Stock · traded 7 June 2011 · filed 7 June 2011
▲ bought on the open market 22,500 shares of CytomedixSEC Form 420 May 2011Common Stock · traded 19 May 2011 · filed 20 May 2011
▲ bought on the open market 15,000 shares of CytomedixSEC Form 420 May 2011Common Stock · traded 20 May 2011 · filed 20 May 2011
▲ bought on the open market 17,500 shares of CytomedixSEC Form 44 May 2011Common Stock · traded 4 May 2011 · filed 4 May 2011
▲ bought on the open market 218,334 shares of CytomedixSEC Form 43 May 2011Common Stock · traded 29 April 2011 · filed 3 May 2011
▲ bought on the open market 33,666 shares of CytomedixSEC Form 43 May 2011Common Stock · traded 2 May 2011 · filed 3 May 2011
▲ bought on the open market 18,000 shares of CytomedixSEC Form 43 May 2011Common Stock · traded 3 May 2011 · filed 3 May 2011
▲ bought on the open market 218,334 shares of CytomedixSEC Form 43 May 2011Common Stock · traded 29 April 2011 · filed 3 May 2011
▲ bought on the open market 33,666 shares of CytomedixSEC Form 43 May 2011Common Stock · traded 2 May 2011 · filed 3 May 2011
acquired or disposed of, other 5,000 shares of CytomedixSEC Form 418 April 2011Common Stock · traded 15 April 2011 · filed 18 April 2011
was granted 10,000 shares of Opexa Therapeutics (a derivative holding)SEC Form 47 April 2011Stock Option (right to buy) · traded 5 April 2011 · filed 7 April 2011
was granted 10,500 shares of Opexa Therapeutics (a derivative holding)SEC Form 47 April 2011Stock Option (right to buy) · traded 5 April 2011 · filed 7 April 2011
▲ bought on the open market 27,500 shares of CytomedixSEC Form 416 March 2011Common Stock · traded 16 March 2011 · filed 16 March 2011
▲ bought on the open market 35,000 shares of CytomedixSEC Form 415 March 2011Common Stock · traded 14 March 2011 · filed 15 March 2011
▲ bought on the open market 12,500 shares of CytomedixSEC Form 415 March 2011Common Stock · traded 15 March 2011 · filed 15 March 2011
▲ bought on the open market 35,000 shares of CytomedixSEC Form 414 March 2011Common Stock · traded 11 March 2011 · filed 14 March 2011

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.